{"id":"NCT03870880","sponsor":"Rovi Pharmaceuticals Laboratories","briefTitle":"Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension","officialTitle":"Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia: Open Label Extension (PRISMA-3_OLE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-25","primaryCompletion":"2020-01-08","completion":"2020-01-08","firstPosted":"2019-03-12","resultsPosted":"2022-02-23","lastUpdate":"2022-03-25"},"enrollment":215,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Risperidone ISM 75 mg","otherNames":[]},{"type":"DRUG","name":"Risperidone ISM 100 mg","otherNames":[]}],"arms":[{"label":"Risperidone ISM 75 mg","type":"EXPERIMENTAL"},{"label":"Risperidone ISM 100 mg","type":"EXPERIMENTAL"}],"summary":"This is the long-term open label extension (OLE) of the study PRISMA-3 (NCT03160521). Those patients who complete participation in the main segment of the study (double blind) together with other clinically stable not previously enrolled (de novo patients) may opt to participate in this extension segment, where they will receive active Risperidone ISM® (75 mg or 100 mg)under open-label conditions every four weeks for approximately 12 months.","primaryOutcome":{"measure":"PANSS Total Score Mean Change From Baseline to Endpoint","timeFrame":"Baseline and Day 365 (or the last post-baseline assessment)","effectByArm":[{"arm":"Rollover Placebo/Risperidone ISM 75 mg","deltaMin":-22.9,"sd":14.15},{"arm":"Rollover Risperidone ISM 75mg/Risperidone ISM 75mg","deltaMin":-11,"sd":14.52},{"arm":"De Novo/Risperidone ISM 75mg","deltaMin":-0.8,"sd":9.39},{"arm":"Rollover Placebo/Risperidone ISM 100 mg","deltaMin":-18.9,"sd":14.61},{"arm":"Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg","deltaMin":-8.7,"sd":13.29},{"arm":"De Novo/Risperidone ISM 100 mg","deltaMin":-4.8,"sd":4.8}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":24,"countries":["United States","Ukraine"]},"refs":{"pmids":["34847501"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":116},"commonTop":["Headache","Nasopharyngitis","Hyperprolactinaemia","Insomnia","Weight increased"]}}